PSTV
Income statement / Annual
Last year (2023), Plus Therapeutics, Inc.'s total revenue was $4.91 M,
an increase of 2,093.30% from the previous year.
In 2023, Plus Therapeutics, Inc.'s net income was -$13.32 M.
See Plus Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$4.91 M
|
$224,000.00
|
$0.00
|
$303,000.00
|
$7.00 M
|
$2.98 M
|
$6.41 M
|
$11.38 M
|
$11.66 M
|
$7.60 M
|
Cost of Revenue |
$9.69 M |
$712,000.00 |
$66,000.00 |
$2.70 M |
$5.37 M |
$1.15 M |
$1.32 M |
$2.72 M |
$3.19 M |
$2.94 M |
Gross Profit |
-$4.78 M |
-$488,000.00 |
-$66,000.00 |
-$2.40 M |
$1.63 M |
$1.84 M |
$5.09 M |
$8.67 M |
$8.47 M |
$4.66 M |
Gross Profit Ratio |
-0.97 |
-2.18 |
0 |
-7.91 |
0.23 |
0.62 |
0.79 |
0.76 |
0.73 |
0.61 |
Research and Development
Expenses |
$9.69 M
|
$9.70 M
|
$5.57 M
|
$3.48 M
|
$5.37 M
|
$5.52 M
|
$13.36 M
|
$16.20 M
|
$19.00 M
|
$15.11 M
|
General & Administrative
Expenses |
$8.54 M
|
$10.24 M
|
$6.85 M
|
$6.41 M
|
$4.82 M
|
$5.58 M
|
$7.59 M
|
$8.56 M
|
$9.77 M
|
$15.95 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$468,000.00
|
$643,000.00
|
$3.59 M
|
$3.61 M
|
$2.66 M
|
$6.41 M
|
Selling, General &
Administrative Expenses |
$8.54 M
|
$10.24 M
|
$6.85 M
|
$6.41 M
|
$5.29 M
|
$6.22 M
|
$11.19 M
|
$12.17 M
|
$12.43 M
|
$22.36 M
|
Other Expenses |
-$9.69 M |
$1,000.00 |
$6,000.00 |
$781,000.00 |
-$1.23 M |
-$470,000.00 |
$13,000.00 |
$233,000.00 |
$169,000.00 |
-$608,000.00 |
Operating Expenses |
$8.54 M |
$19.94 M |
$12.43 M |
$9.89 M |
$10.66 M |
$11.75 M |
$25.78 M |
$28.37 M |
$31.43 M |
$37.46 M |
Cost And Expenses |
$18.23 M |
$19.94 M |
$12.43 M |
$9.89 M |
$10.66 M |
$11.75 M |
$27.09 M |
$31.09 M |
$34.61 M |
$40.40 M |
Interest Income |
$400,000.00 |
$147,000.00 |
$19,000.00 |
$50,000.00 |
$55,000.00 |
$43,000.00 |
$33,000.00 |
$19,000.00 |
$9,000.00 |
$6,000.00 |
Interest Expense |
$395,000.00 |
$711,000.00 |
$932,000.00 |
$1.11 M |
$1.86 M |
$1.92 M |
$2.05 M |
$2.59 M |
$3.38 M |
$4.37 M |
Depreciation &
Amortization |
$628,000.00
|
$712,000.00
|
$419,000.00
|
$369,000.00
|
$441,000.00
|
$379,000.00
|
$2.15 M
|
$1.18 M
|
$1.09 M
|
$779,000.00
|
EBITDA |
-$12.69 M
|
-$18.85 M
|
-$12.49 M
|
-$6.77 M
|
-$987,000.00
|
-$6.58 M
|
-$18.49 M
|
-$18.27 M
|
-$14.27 M
|
-$32.22 M
|
EBITDA Ratio |
-2.58 |
-84.58 |
0 |
-30.26 |
-0.39 |
-2.25 |
-2.88 |
-1.61 |
-1.86 |
-4.29 |
Operating Income Ratio
|
-2.71
|
-88
|
0
|
-31.63
|
-0.52
|
-2.94
|
-3.23
|
-1.73
|
-1.31
|
-4.27
|
Total Other
Income/Expenses Net |
$5,000.00
|
-$563,000.00
|
-$907,000.00
|
$1.34 M
|
$374,000.00
|
-$116,000.00
|
-$2.00 M
|
-$2.34 M
|
-$3.46 M
|
-$4.93 M
|
Income Before Tax |
-$13.32 M |
-$20.28 M |
-$13.40 M |
-$8.24 M |
-$3.28 M |
-$8.88 M |
-$22.69 M |
-$22.05 M |
-$18.74 M |
-$37.37 M |
Income Before Tax Ratio
|
-2.71
|
-90.51
|
0
|
-27.2
|
-0.47
|
-2.98
|
-3.54
|
-1.94
|
-1.61
|
-4.92
|
Income Tax Expense |
$0.00 |
$563,000.00 |
$932,000.00 |
$1.11 M |
$9.46 M |
$1.99 M |
$2.06 M |
$2.83 M |
$3.55 M |
$3.76 M |
Net Income |
-$13.32 M |
-$20.84 M |
-$14.33 M |
-$9.35 M |
-$12.74 M |
-$12.63 M |
-$22.69 M |
-$22.05 M |
-$18.74 M |
-$37.37 M |
Net Income Ratio |
-2.71 |
-93.03 |
0 |
-30.85 |
-1.82 |
-4.24 |
-3.54 |
-1.94 |
-1.61 |
-4.92 |
EPS |
-4.24 |
-11.91 |
-17.78 |
-31.67 |
-138.1 |
-1090.08 |
-5253.82 |
-9564.43 |
-14983.21 |
-40310.68 |
EPS Diluted |
-4.24 |
-11.91 |
-17.78 |
-31.67 |
-138.1 |
-1090.08 |
-5253.82 |
-9564.43 |
-14983.21 |
-40310.68 |
Weighted Average Shares
Out |
$3.14 M
|
$1.75 M
|
$805,945.00
|
$295,189.00
|
$92,267.00
|
$11,590.00
|
$4,318.00
|
$2,305.00
|
$1,251.00
|
$927.00
|
Weighted Average Shares
Out Diluted |
$3.14 M
|
$1.75 M
|
$805,945.00
|
$295,189.00
|
$92,267.00
|
$11,590.00
|
$4,318.00
|
$2,305.00
|
$1,251.00
|
$927.00
|
Link |
|
|
|
|
|
|
|
|
|
|